In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Sticks To Status Quo On Clinical Research Coverage, For Now

This article was originally published in The Gray Sheet

Executive Summary

Major revisions to CMS' policy on covering clinical research costs were put on hold July 9 in response to stakeholder demands for more input

You may also be interested in...



CMS Maintains Status Quo On Clinical Trial Coverage, Again

Under intense pressure from Congress, industry and the medical research community, CMS has decided to maintain the status quo for coverage of routine costs in clinical trials

CMS Maintains Status Quo On Clinical Trial Coverage, Again

Under intense pressure from Congress, industry and the medical research community, CMS has decided to maintain the status quo for coverage of routine costs in clinical trials

CMS Gives Boston Scientific Another Chance To Gain Brain Stent Coverage

CMS will reassess its national Medicare non-coverage policy on intracranial stenting and angioplasty, the agency announced Aug. 24

Related Content

UsernamePublicRestriction

Register

MT025018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel